Back to Search Start Over

The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt.

Authors :
Sweed, Dina
Sweed, Enas
Moaz, Inas
Mosbeh, Asmaa
Fayed, Yahya
Elhamed, Sara Mohamed Abd
Sweed, Eman
Macshut, Mahmoud
Abdelsattar, Shimaa
Kilany, Shimaa
Saied, Sara A.
Badr, Reda
Abdallah, Mahmoud S.
Ehsan, Nermine
Source :
World Journal of Surgical Oncology; 9/19/2022, Vol. 20 Issue 1, p1-19, 19p
Publication Year :
2022

Abstract

Background: Hepatocellular carcinoma (HCC) remains a major health problem despite the emergence of several preventive and therapeutic modalities. HCC has heterogeneous and wide morpho-molecular patterns, resulting in unique clinical and prognostic criteria. Therefore, we aimed to study the clinical and pathological criteria of HCC to update the morpho-molecular classifications and provide a guide to the diagnosis of this disease. Methods: Five hundred thirty pathologically analyzed HCC cases were included in this study. The clinical and survival data of these cases were collected. Results: Hepatitis C virus is still the dominant cause of HCC in Egypt. Post-direct-acting antiviral agent HCC showed an aggressive course compared to interferon-related HCC. Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver were important prognostic parameters. Special HCC variants have characteristic clinical, laboratory, radiological, prognostic, and survival data. Tumor-infiltrating lymphocytes rather than neutrophil-rich HCC have an excellent prognosis. Conclusions: HCC is a heterogenous tumor with diverse clinical, pathological, and prognostic parameters. Incorporating the clinicopathological profile per specific subtype is essential in the treatment decision of patients with HCC. Trial registration: This was a retrospective study that included 530 HCC cases eligible for analysis. The cases were obtained from the archives of the Pathology Department, during the period between January 2010 and December 2019. Clinical and survival data were collected from the patients' medical records after approval by the institutional review board (IRB No. 246/2021) of Liver National Institute, Menoufia University. The research followed the guidelines outlined in the Declaration of Helsinki and registered on ClinicalTrials.gov (NCT05047146). [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14777819
Volume :
20
Issue :
1
Database :
Complementary Index
Journal :
World Journal of Surgical Oncology
Publication Type :
Academic Journal
Accession number :
159161942
Full Text :
https://doi.org/10.1186/s12957-022-02764-2